USP comments to FDA on Docket No. FDA-2017-D-5767 for "ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin". Comments were submitted in 2018.
Public Policy
-
Diversity, equity, inclusion and belonging at USPUSP aspires to be a diverse, inclusive, innovative, and engaging organization that empowers and engages staff and volunteers.
History of USPUSP has been building trust in medicine for over 200 years.
-
Promoting the Quality of Medicines Plus (PQM+) annual reportThe goal of the PQM+ Program is to sustainably strengthen medical product quality assurance systems in low and middle-income countries.
APEC Supply Chain Security ToolkitThe Toolkit is a resource that addresses areas of vulnerability in the medical product supply chain through prevention, detection, and response strategies and actions.
Complex GenericsAddressing barriers to the development of complex generics: Understanding challenges and opportunities.